Gene and Cell Therapies entered the market with the promise of providing a durable treatment for some of the most common chronic conditions. Many of these drugs can cost hundreds of thousands if not millions of dollars per dose. Until recently, the majority of these novel therapies have targeted rare and orphan diseases; however, over the next 10 years durable therapies that are indicated for more common conditions, like forms of anemia and hemophilia, are likely to hit the market.
This Advisory Board webtool enables users to see which gene and cell therapies have a greater than 50% chance of entering the market within the next few years, based on pipeline forecast data provided by Evaluate Pharma.
The web tool also includes more detailed information about each therapy’s:
- Incidence Rate
- Probability of trial success
- Estimated market arrival